AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19114190
Drug: Special acupuncture
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special acupuncture technique (preoperative implantation of small intradermal needles retained for 4 weeks)
Trial: 17136231
Drug: Prophylactic administration
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic administration of ibuprofen on the first day of life
Trial: 17136231
Drug: Therapeutic administration
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic administration of ibuprofen to induce closure of a symptomatic PDA
Trial: 7826833
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose metoclopramide (7 mg kg‐1 day‐1)
Trial: 7826833
Drug: Alizapride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride (5 mg kg‐1 day‐1)
Trial: 21926189
Drug: Tailored cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored cognitive-behavioural therapy and exercise training (16 twice-weekly sessions)
Trial: 17209739
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of kinship information from two halves of the face
Trial: 12850126
Drug: Levodropropizine 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodropropizine 6% drops administered orally t.i.d. for 10 consecutive administrations
Trial: 1555693
Drug: Short regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short regimen of gonadotropin-releasing hormone agonist
Trial: 1555693
Drug: Long regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long regimen of gonadotropin-releasing hormone agonist
Trial: 22370698
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg oral melatonin daily for 4 months
Trial: 20822027
Drug: Rocephin 2
RxNorm normalized name: Rocephin 2g Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocephin 2 g once daily for 7 days
Trial: 10430393
Drug: Hypoxic upper
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxic upper abdominal chemotherapy (Mitomycin‐C, 5‐Fluorouracil, Leucovorin, Farmorubicin) plus systemic chemotherapy
Trial: 10430393
Drug: Hypoxic upper
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxic upper abdominal chemotherapy (Mitomycin‐C, 5‐Fluorouracil, Leucovorin, Farmorubicin) without systemic chemotherapy
Trial: 10430393
Drug: No neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No neo or adjuvant treatment
Trial: 7571220
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg/day for 3 months (after a 3-week titration period)
Trial: 7571220
Drug: Doxazosin 8
RxNorm normalized name: doxazosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 8 mg/day for 3 months (after a 3-week titration period)
Trial: 7571220
Drug: Doxazosin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin administered in the morning or evening
Trial: 2076734
Drug: Co-dergocrine mesylate
RxNorm normalized name: co-dergocrine mesylate
DrugBank: Ergoloid mesylate (DB01049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-dergocrine mesylate (Cod) 4 mg followed by Nifedipine (Nif) 20 mg
Trial: 2076734
Drug: Nifedipine (Nif)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (Nif) 20 mg with placebo as premedication
Trial: 2076734
Drug: Nifedipine (Nif)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (Nif) 20 mg with Cod as premedication
Trial: 2076734
Drug: Nifedipine (Nif)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (Nif) 20 mg
Trial: 495541
Drug: Thiamin intake
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamin intake of 0.30 mg per 1000 kcal (derived from carbohydrate sources)
Trial: 495541
Drug: Thiamin intake
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamin intake of 0.40 mg per 1000 kcal (recommended by FAO/WHO)
Trial: 495541
Drug: Thiamin intake
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamin intake of 0.5 mg per 1000 kcal (recommended by Food and Nutrition Board of NAS‐NRC)
Trial: 495541
Drug: Erythrocyte transketolase
RxNorm normalized name: erythrocytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythrocyte transketolase activity and urinary excretion of thiamin
Trial: 31480045
Drug: Pantoprazole (intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (intravenously once daily during ICU stay, until ICU discharge, death, or a maximum of 90 days)
Trial: 31480045
Drug: Placebo (intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenously once daily during ICU stay, until ICU discharge, death, or a maximum of 90 days)
Trial: 28538380
Drug: Cinacalcet (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (30 mg)
Trial: 21879181
Drug: Rectal ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal ozone therapy
Trial: 21879181
Drug: Rectal medicinal
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal medicinal oxygen
Trial: 11503783
Drug: Cisplatin (monotherapy)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (monotherapy)
Trial: 8384187
Drug: ECA (ephedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECA (ephedrine 75‐150mg, caffeine 150mg, aspirin 330mg)
Trial: 3519551
Drug: Once-a-week radiation
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-a-week radiation therapy (1 X W) - 6000 rad using 500 rad fractions for 12 weeks
Trial: 3519551
Drug: Daily radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily radiation therapy (5 X W) - 6000 rad using 200 rad fractions for 6 weeks
Trial: 30885221
Drug: Armolipid Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armolipid Plus (AP) - 500 mg berberine, 3 mg monacolin K, 10 mg policosanol, once daily for 24 weeks
Trial: 30885221
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) - once daily for 24 weeks
Trial: 25161155
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg empagliflozin with 40 mg simvastatin
Trial: 14607714
Drug: Electro-acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture therapy (EAT) in combination with liver artery intubation chemotherapy (Group A)
Trial: 14607714
Drug: Electro-acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture therapy (EAT) alone (Group B)
Trial: 14607714
Drug: Liver artery
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver artery intubation chemotherapy alone (Group C)
Trial: 7744151
Drug: Pyridoxine administration
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine administration
Trial: 2282207
Drug: Magnesium supplement
RxNorm normalized name: Magnesium supplement
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium supplement
Trial: 6786067
Drug: diltiazem (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem (120 mg/day)
Trial: 6786067
Drug: diltiazem (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem (240 mg/day)
Trial: 30626095
Drug: 4-day protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day protein restricted diet (0.25 g protein/kg body weight/day)
Trial: 30626095
Drug: Habitual diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habitual diet (1.3 ± 0.3 g protein/kg body weight/day)
Trial: 25391549
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone ER tablet with low-level coating
Trial: 25391549
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone ER tablet with intermediate-level coating
Trial: 25391549
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone ER tablet with high-level coating
Trial: 25391549
Drug: Hydrocodone IR/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone IR/acetaminophen (APAP) 10/325 mg
Trial: 23832726
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist group (Group A) - r‐FSH (50‐75 IU/d) plus cetrorelix (0.25 mg/d) starting when ≥ 2 follicles ≥ 14 mm were detected on ultrasound scan.
Trial: 23832726
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist group (Group A)
Trial: 20942865
Drug: MPT (melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPT (melphalan 9 mg/m²/d for 4 days every 6 weeks, prednisone 60 mg/m²/d for 4 days every 6 weeks, thalidomide 100 mg/d continuously)
Trial: 20942865
Drug: MP (melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP (melphalan 9 mg/m²/d for 4 days every 6 weeks, prednisone 60 mg/m²/d for 4 days every 6 weeks)
Trial: 19604191
Drug: Oral triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral triiodothyronine (T(3)) replacement therapy, 20 microg every 12 h starting just before induction of anaesthesia until the first day after surgery
Trial: 19604191
Drug: Oral triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral triiodothyronine (T(3)) replacement therapy
Trial: 16262513
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for delinquency and alcohol and/or marijuana use disorders
Trial: 7483800
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine containing the Urabe mumps strain
Trial: 7483800
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine containing the Jeryl Lynn mumps strain
Trial: 7483800
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine containing the Schwarz strain
Trial: 7483800
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine (all types)
Trial: 30541641
Drug: Volume Controlled
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume Controlled Ventilation (VCV) with 7 L/min atomized oxygen flow
Trial: 30541641
Drug: Pressure Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure Controlled Ventilation (PCV) with 9 L/min atomized oxygen flow
Trial: 30541641
Drug: Simulated scuba
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated scuba test under VCV mode with 9 L/min atomized oxygen flow
Trial: 30541641
Drug: Simulated scuba
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated scuba test under PCV mode with 9 L/min atomized oxygen flow
Trial: 25551178
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy for impetigo
Trial: 16575135
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate 125 mg twice daily along with macrolides (azitromycin for five days)
Trial: 16575135
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated only with antibiotics (macrolides)
Trial: 10194656
Drug: Fosinopril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (ACE inhibitor), 12 weeks treatment
Trial: 8946872
Drug: 5‐FU chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU chemotherapy via pelvic retroperitoneal cannulation
Trial: 6763175
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution or air
Trial: 31331575
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (RM and HRV-BF)
Trial: 23337728
Drug: Odanacatib 50
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib 50 mg weekly
Trial: 19835115
Drug: Alternate acupuncture
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate acupuncture group (opposing needling and non-opposing needling, twice daily)
Trial: 19835115
Drug: Routine acupuncture
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine acupuncture group (acupuncture at the affected side, once daily)
Trial: 11594943
Drug: High-dose antioxidant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose antioxidant formulation (vitamin C, 500 mg; vitamin E, 400 IU; beta carotene, 15 mg)
Trial: 9692520
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg orally once a day for 3 days
Trial: 3211806
Drug: Combined intramuscular
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intramuscular and oral estrogen treatment (ESTR, n = 41)
Trial: 3211806
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (ORX and ESTR)
Trial: 23486236
Drug: Probiotic lozenges
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lozenges containing L. reuteri (DSM 17938 and ATCC PTA 5289; 1 × 10(8) CFU of each strain), 2/day
Trial: 23486236
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges lacking lactobacilli
Trial: 18768332
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg qd
Trial: 18768332
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg bid
Trial: 8186346
Drug: Tripotassium dicitrato
RxNorm normalized name: Tripotassium dicitratobismuthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripotassium dicitrato bismuthate one tablet q.d.s
Trial: 3035166
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral hygiene regimen
Trial: 23419093
Drug: Keratinocyte growth
RxNorm normalized name: Keratinocyte growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keratinocyte growth factor (palifermin, 60 μg/kg)
Trial: 20544030
Drug: Clinician-assisted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-assisted treatment
Trial: 20544030
Drug: Technician-assisted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technician-assisted treatment
Trial: 16631431
Drug: 6% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% carbohydrate solution (n=8)
Trial: 16631431
Drug: 6-g essential
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-g essential amino acid mixture (n=8)
Trial: 16631431
Drug: Combined carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined carbohydrate and essential amino acid supplement (n=8)
Trial: 9553683
Drug: Controfilina-200 (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controfilina-200 (test preparation)
Trial: 3189898
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 2.5 mg
Trial: 26336919
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium bicarbonate (3 ml/kg/h for 1 h; n = 43)
Trial: 26336919
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium citrate (75 ml/10 kg divided into 4 doses; n = 43)
Trial: 24252587
Drug: Grief-Help (cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grief-Help (cognitive behavioural treatment) combined with five sessions of parental counselling
Trial: 18768432
Drug: Depot octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot octreotide (100 microg subcutaneously on day 1, followed by 20 mg intramuscularly on days 2 and 29)
Trial: 17137546
Drug: Antibiotics (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (oral trimethoprim-sulfamethoxazole, amoxicillin, or doxycycline)
Trial: 9370552
Drug: ProHance administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProHance administered at doses ranging from 0.1 mmol/kg to 0.3 mmol/kg
Trial: 9370552
Drug: ProHance at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProHance at a higher dose level of 0.3 mmol/kg
Trial: 1383099
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 micrograms) administered intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP
Trial: 22961907
Drug: Bilberry diet
RxNorm normalized name: Bilberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilberry diet (400 g fresh bilberries daily)
Trial: 30178742
Drug: Voglibose plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose plus metformin
Trial: 30178742
Drug: Individual voglibose
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual voglibose and metformin tablets
Trial: 30178742
Drug: Individual voglibose
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual voglibose and metformin tablets and FDC
Trial: 8643018
Drug: High-dosed intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosed intravenous immunoglobulins (0.4 g/kg/daily for five days)
Trial: 8643018
Drug: Corticosteroids (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (500 mg methylprednisolone daily for five days)
Trial: 8643018
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with high dose methylprednisolone and immunoglobulins
Trial: 8643018
Drug: General medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General medical care and supportive therapy in the intensive care unit
Trial: 7022706
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose carbenicillin prophylaxis preoperatively
Trial: 31794130
Drug: Ca+ channel
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca+ channel blocker (verapamil or nicardipine)
Trial: 23989522
Drug: 4 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg/day prednisolone (group A, n = 35)
Trial: 23989522
Drug: 2 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg/day prednisolone (group B, n = 34)
Trial: 19996400
Drug: Inhaled oxygen
RxNorm normalized name: oxygen Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled oxygen at 100%, 12 L/min, delivered by face mask for 15 minutes.
Trial: 2821808
Drug: Alginate/antacid compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate/antacid compound (5 g four times a day)
Trial: 30668179
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% Potassium hydroxide (KOH) gel applied once daily up to clearing (maximum 30 days)
Trial: 30668179
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% Potassium hydroxide (KOH) gel
Trial: 27350144
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injection in the medial orbicularis muscle of the lower eyelid
Trial: 26153128
Drug: atrasentan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atrasentan (both doses)